View Older Stories View More Recent Stories

Nov 2, 2018 07:47AM AbbVie Reports Third-Quarter 2018 Financial Results
Nov 1, 2018 07:11AM From pharma to prisons, election-sensitive stocks that could swing
Nov 1, 2018 05:59AM AbbVie (ABBV) Granted European Commission Approval of VENCLYXTO (venetoclax) Plus Rituximab
Nov 1, 2018 12:02AM AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Oct 31, 2018 04:54PM AbbVie (ABBV) Phase 3 Trial Evaluating Venetoclax Combination as First-Line Therapy in CLL Met its Primary Endpoint
Oct 31, 2018 04:14PM AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia
Oct 24, 2018 04:09PM AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Oct 23, 2018 09:00AM AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
Oct 22, 2018 06:01PM Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis
Oct 18, 2018 08:51AM AbbVie (ABBV) Announces Global Resolution of HUMIRA Patent Disputes with Fresenius
Oct 18, 2018 08:50AM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi
Oct 18, 2018 08:03AM AbbVie (ABBV), Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Oct 18, 2018 08:00AM AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Oct 17, 2018 08:04AM AbbVie (ABBV) Announces sNDA Accepted for Priority Review by FDA for IMBRUVICA in Combination with Obinutuzumab for Previously Untreated CLL
Oct 17, 2018 08:00AM AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lym
Oct 16, 2018 12:42PM AbbVie (ABBV) Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at UEG
Oct 16, 2018 12:38PM AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
Oct 11, 2018 04:33PM AbbVie (ABBV) Announces Resolution of HUMIRA Patent Disputes with Sandoz
Oct 11, 2018 04:32PM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz
Oct 8, 2018 08:41AM AbbVie (ABBV) to Present New Data for Upadacitinib and HUMIRA at ACR/ARHP Meeting
Oct 8, 2018 08:33AM AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
Sep 21, 2018 07:30AM AbbVie (ABBV) Announces Positive CHMP Opinion for Combination of VENCLYXTO with Rituximab
Sep 21, 2018 07:27AM AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymph
Sep 17, 2018 08:00AM AbbVie to Host Third-Quarter 2018 Earnings Conference Call
Sep 13, 2018 09:20AM AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Sep 13, 2018 06:24AM AbbVie (ABBV) Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing 'Significant Improvements' in Health-Related Quality of Life
Sep 13, 2018 06:20AM AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Sep 11, 2018 08:21AM AbbVie (ABBV) Says Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA Label
Sep 11, 2018 08:17AM Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
Sep 7, 2018 11:23AM AbbVie Declares Quarterly Dividend
Sep 4, 2018 09:00AM AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Aug 28, 2018 08:00AM AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
Aug 22, 2018 08:33AM AbbVie (ABBV), Neurocrine (NBIX) Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 22, 2018 08:30AM AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 22, 2018 06:01AM argenx (ARGX) Reports Exclusive Option Exercise by AbbVie (ABBV) to Develop and License ARGX-115
Aug 17, 2018 08:06AM AbbVie (ABBV) Enters Clinical Research Collaboration with Tolero Pharmaceuticals, Inc. for Acute Myeloid Leukemia Trial
Aug 7, 2018 08:16AM Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
Jul 27, 2018 07:38AM AbbVie Reports Second-Quarter 2018 Financial Results
Jul 27, 2018 07:26AM Tech stocks weigh on Wall Street
Jul 24, 2018 08:31AM AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Secure FDA Approval of ORILISSA (elagolix)
Jul 24, 2018 08:30AM AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Jul 17, 2018 08:06AM AbbVie (ABBV) Granted HUMIRA (adalimumab) Patent License with Mylan (MYL)
Jul 17, 2018 08:05AM AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan
Jul 12, 2018 05:59AM AbbVie (ABBV) Reports Submission of Supplemental New Drug Application to FDA for Venetoclax
Jul 12, 2018 01:01AM AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Jul 11, 2018 08:01AM AbbVie (ABBV) Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer DLBCL and Ongoing Ibrutinib Clinical Program
Jul 11, 2018 08:00AM AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program
Jul 10, 2018 08:00AM AbbVie to Host Second-Quarter 2018 Earnings Conference Call
Jun 26, 2018 08:04AM AbbVie (ABBV) & Calico Report Extension of Collaboration to Research New Therapies for Age-Related Diseases
Jun 26, 2018 08:00AM AbbVie and Calico Announce Extension of Groundbreaking Collaboration
View More Recent Stories View Older Stories